PURPOSE: To assess the impact of duration of topical steroid treatment on the incidence of endothelial graft rejection following normal-risk penetrating keratoplasty (PK). DESIGN: Prospective, institutional, longitudinal, randomized interventional trial including 406 eyes (age: 5219 years; follow-up: 4218 months). METHODS: Postoperative treatment started with prednisolone acetate 1% eye drops five times daily and was tapered over the first 6 months. Patients were then randomised into either short-term (stop topical steroid treatment) or long-term treatment (continue steroids once daily until 12 months). RESULTS: During follow-up, 29 eyes (7.1%) developed an episode of endothelial graft rejection. Graft rejections were significantly more common in the short-term (19 of 202; 9.1%) compared to the long-term treatment group (10 of 204: 4.9%; p=0.001). CONCLUSIONS: Long-term low-dose topical steroid treatment protects against immunological graft rejections.
Primary Outcome Measures:
Estimated Enrollment: |
400 |
Study Start Date: |
January 1999 |
Study Completion Date: |
March 2007 |
PURPOSE: To assess the impact of duration of topical steroid treatment on the incidence of endothelial graft rejection following normal-risk penetrating keratoplasty (PK). DESIGN: Prospective, institutional, longitudinal, randomized interventional trial including 406 eyes (age: 5219 years; follow-up: 4218 months). METHODS: Postoperative treatment started with prednisolone acetate 1% eye drops five times daily and was tapered over the first 6 months. Patients were then randomised into either short-term (stop topical steroid treatment) or long-term treatment (continue steroids once daily until 12 months). RESULTS: During follow-up, 29 eyes (7.1%) developed an episode of endothelial graft rejection. Graft rejections were significantly more common in the short-term (19 of 202; 9.1%) compared to the long-term treatment group (10 of 204: 4.9%; p=0.001). CONCLUSIONS: Long-term low-dose topical steroid treatment protects against immunological graft rejections.